{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:05:13Z","timestamp":1792479913340,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG07664, AG057557, AG061388, and AG062272"],"award-info":[{"award-number":["AG07664, AG057557, AG061388, and AG062272"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["AA029831"],"award-info":[{"award-number":["AA029831"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are approved for treating type 2 diabetes and weight loss. There have been concerns that GLP-1RAs may increase the risk of intestinal obstruction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Investigate the association between GLP-1RAs use and intestinal obstruction in a large cohort of patients with type 2 diabetes mellitus (T2DM) in the U.S.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using longitudinal electronic health records sourced from TriNetX, a large-scale, population-based health database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The study included over 1.2\u00a0million T2DM patients who were prescribed anti-diabetic medications, including 181,795 prescribed GLP-1RAs between April 2013 and April 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main measures<\/jats:title>\n                    <jats:p>The incidence of intestinal obstruction was compared between GLP-1RAs and each of six other classes of non-GLP-1RA anti-diabetic medications. Hazard ratios (HRs) at 1, 3, and 5-year follow-up periods were calculated using Cox proportional hazards analysis. Separate analyses were performed in T2DM patients with and without obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key results<\/jats:title>\n                    <jats:p>The risk of intestinal obstruction did not differ between GLP-1RAs and other anti-diabetic medications except for a reduced risk compared with insulins. The results were consistent for 1, 3, and 5-year follow-up periods and in patients with and without obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings do not support an increased risk of intestinal obstruction in T2DM patients prescribed GLP-1 RAs compared to other anti-diabetic medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00592-025-02525-z","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T02:54:12Z","timestamp":1749092052000},"page":"1941-1951","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Association of GLP-1 receptor agonists with risk of intestinal obstruction in patients with type 2 diabetes mellitus: a retrospective cohort study"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-5092","authenticated-orcid":false,"given":"Zhenxiang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Tabernacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Dorney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingjian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kaelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"2525_CR1","doi-asserted-by":"crossref","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC (2024) GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine 75","DOI":"10.1016\/j.eclinm.2024.102782"},{"issue":"4","key":"2525_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1464-5491.2007.02106.x","volume":"24","author":"CM Bennett","year":"2007","unstructured":"Bennett CM, Guo M, Dharmage SC (2007) HbA1c as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 24(4):333\u2013343","journal-title":"Diabet Med"},{"key":"2525_CR3","doi-asserted-by":"crossref","unstructured":"Scheen AJ (2023) Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: a narrative review. Diabetes Metab 101508","DOI":"10.1016\/j.diabet.2023.101508"},{"issue":"6","key":"2525_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1365-2982.2008.01246.x","volume":"21","author":"J Schirra","year":"2009","unstructured":"Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, G\u00f6ke B (2009) GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neurogastroenterology Motil 21(6):609\u2013e22","journal-title":"Neurogastroenterology Motil"},{"issue":"6","key":"2525_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1365-2982.2007.01079.x","volume":"20","author":"PM Hellstr\u00f6m","year":"2008","unstructured":"Hellstr\u00f6m PM, N\u00e4slund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E, Efendic S (2008) GLP-1 suppresses Gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 20(6):649\u2013659","journal-title":"Neurogastroenterol Motil"},{"issue":"1\u20133","key":"2525_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0167-0115(02)00054-X","volume":"106","author":"E N\u00e4slund","year":"2002","unstructured":"N\u00e4slund E, Skogar S, Efendic S, Hellstr\u00f6m PM (2002) Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin. Regul Pept 106(1\u20133):89\u201395","journal-title":"Regul Pept"},{"issue":"5","key":"2525_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/gut.46.5.622","volume":"46","author":"J Schirra","year":"2000","unstructured":"Schirra J, Houck P, Wank U, Arnold R, G\u00f6ke B, Katschinski M (2000) Effects of glucagon-like peptide-1 (7\u201336) amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 46(5):622\u2013631","journal-title":"Gut"},{"issue":"4","key":"2525_CR8","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1172\/JCI942","volume":"102","author":"T Tolessa","year":"1998","unstructured":"Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstr\u00f6m PM (1998) Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Investig 102(4):764\u2013774","journal-title":"J Clin Investig"},{"issue":"1","key":"2525_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0002-9610(00)00407-4","volume":"180","author":"G Miller","year":"2000","unstructured":"Miller G, Boman J, Shrier I, Gordon PH (2000) Etiology of small bowel obstruction. Am J Surg 180(1):33\u201336","journal-title":"Am J Surg"},{"key":"2525_CR10","doi-asserted-by":"crossref","unstructured":"Drucker DJ (2024) Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care dci240003","DOI":"10.2337\/dci24-0003"},{"key":"2525_CR11","doi-asserted-by":"crossref","unstructured":"Ludvigsson JF, Almqvist C, Bonamy AKE, Ljung R, Micha\u00eblsson K, Neovius M, Ye W (2016) Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31:125\u2013136","DOI":"10.1007\/s10654-016-0117-y"},{"key":"2525_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","volume":"29","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Pedersen L, S\u00f8rensen HT (2014) The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 29:541\u2013549","journal-title":"Eur J Epidemiol"},{"issue":"Supplement1","key":"2525_CR13","first-page":"bvad114","volume":"7","author":"S Alqaisi","year":"2023","unstructured":"Alqaisi S, Doerfler WR, Latif T, Bandi A (2023) SAT675 GLP-1RA therapy and intussusception: a case report of bowel telescoping in Anobese patient after successful weight loss on therapy. J Endocr Soc 7(Supplement1):bvad114\u2013123","journal-title":"J Endocr Soc"},{"issue":"5","key":"2525_CR14","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.apsb.2023.02.020","volume":"13","author":"J Lu","year":"2023","unstructured":"Lu J, Liu H, Zhou Q, Wang MW, Li Z (2023) A potentially serious adverse effect of GLP-1 receptor agonists. Acta Pharm Sinica B 13(5):2291","journal-title":"Acta Pharm Sinica B"},{"issue":"1","key":"2525_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/cpt.2430","volume":"111","author":"JL Faillie","year":"2022","unstructured":"Faillie JL, Yin H, Yu OH, Herrero A, Altwegg R, Renoux C, Azoulay L (2022) Incretin-Based drugs and risk of intestinal obstruction among patients with type 2 diabetes. Clin Pharmacol Ther 111(1):272\u2013282","journal-title":"Clin Pharmacol Ther"},{"key":"2525_CR16","doi-asserted-by":"crossref","unstructured":"Ueda P, Wintzell V, Melbye M, Eliasson B, S\u00f6derling J, Gudbj\u00f6rnsdottir S, Pasternak B (2023) Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study. Clin Gastroenterol Hepatol","DOI":"10.1016\/j.cgh.2023.08.034"},{"key":"2525_CR17","doi-asserted-by":"crossref","unstructured":"Palchuk MB, London JW, Perez-Rey D, Drebert ZJ, Winer-Jones JP,Thompson CN, Claerhout B (2023) A global federated real-world data and analytics platform for research. JAMIA Open 6(2):ooad035","DOI":"10.1093\/jamiaopen\/ooad035"},{"issue":"10","key":"2525_CR18","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","volume":"66","author":"M Anson","year":"2023","unstructured":"Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U (2023) SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia 66(10):1869\u20131881","journal-title":"Diabetologia"},{"issue":"8","key":"2525_CR19","doi-asserted-by":"publisher","first-page":"e2427258","DOI":"10.1001\/jamanetworkopen.2024.27258","volume":"7","author":"MH Chuang","year":"2024","unstructured":"Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC (2024) Clinical outcomes of Tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open 7(8):e2427258\u2013e2427258","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2525_CR20","doi-asserted-by":"publisher","first-page":"e2439887","DOI":"10.1001\/jamanetworkopen.2024.39887","volume":"7","author":"MG Miller","year":"2024","unstructured":"Miller MG, Terebuh P, Kaelber DC, Xu R, Davis PB (2024) Characterizing GLP-1 receptor agonist use in preadolescent and adolescent populations. JAMA Netw Open 7(10):e2439887\u2013e2439887","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2525_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","volume":"10","author":"L Wang","year":"2024","unstructured":"Wang L, Wang W, Kaelber DC, Xu R, Berger NA (2024) GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight\/obesity. JAMA Oncol 10(2):256\u2013258","journal-title":"JAMA Oncol"},{"key":"2525_CR22","doi-asserted-by":"crossref","unstructured":"Wang L, Berger NA, Kaelber DC, Xu R (2024) Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes. Gastroenterology","DOI":"10.1053\/j.gastro.2024.04.029"},{"key":"2525_CR23","doi-asserted-by":"crossref","unstructured":"Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R (2024) Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med 1\u20139","DOI":"10.1038\/s41591-023-02672-2"},{"issue":"7","key":"2525_CR24","doi-asserted-by":"publisher","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA (2024) Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open 7(7):e2421305\u2013e2421305","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2525_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/nu12010111","volume":"12","author":"S Emerenziani","year":"2019","unstructured":"Emerenziani S, Pier Luca Guarino M, Trillo Asensio LM, Altomare A, Ribolsi M, Balestrieri P, Cicala M (2019) Role of overweight and obesity in gastrointestinal disease. Nutrients 12(1):111","journal-title":"Nutrients"},{"issue":"3","key":"2525_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399\u2013424","journal-title":"Multivar Behav Res"},{"key":"2525_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1590\/S0104-11692008000200011","volume":"16","author":"IDR Carolino","year":"2008","unstructured":"Carolino IDR, Molena-Fernandes CA, Tasca RS, Marcon SS, Cuman RK N (2008) Risk factors in patients with type 2 diabetes mellitus. Rev Latinoam Enferm 16:238\u2013244","journal-title":"Rev Latinoam Enferm"},{"issue":"7","key":"2525_CR28","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1185\/03007995.2016.1168291","volume":"32","author":"K Iglay","year":"2016","unstructured":"Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, Rajpathak S (2016) Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opinion 32(7):1243\u20131252","journal-title":"Curr Med Res Opinion"},{"key":"2525_CR29","first-page":"14","volume":"65","author":"L Bordeianou","year":"2020","unstructured":"Bordeianou L, Yeh DD (2020) Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults. UpToDate Com 65:14","journal-title":"UpToDate Com"},{"issue":"04","key":"2525_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1055\/s-0041-1729927","volume":"34","author":"WR Johnson","year":"2021","unstructured":"Johnson WR, Hawkins AT (2021) Large bowel obstruction. Clin Colon Rectal Surg 34(04):233\u2013241","journal-title":"Clin Colon Rectal Surg"},{"key":"2525_CR31","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes\u2013state-of-the-art. Mol Metabolism 46:101102","journal-title":"Mol Metabolism"},{"issue":"4","key":"2525_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bph.15611","volume":"179","author":"JJ Holst","year":"2022","unstructured":"Holst JJ, Andersen DB, Grunddal KV (2022) Actions of glucagon-like peptide\u20101 receptor ligands in the gut. Br J Pharmacol 179(4):727\u2013742","journal-title":"Br J Pharmacol"},{"key":"2525_CR33","doi-asserted-by":"publisher","first-page":"1347047","DOI":"10.3389\/fphar.2024.1347047","volume":"15","author":"M Cheng","year":"2024","unstructured":"Cheng M, Ren L, Jia X, Wang J, Cong B (2024) Understanding the action mechanisms of Metformin in the Gastrointestinal tract. Front Pharmacol 15:1347047","journal-title":"Front Pharmacol"},{"key":"2525_CR34","doi-asserted-by":"publisher","first-page":"975912","DOI":"10.3389\/fendo.2022.975912","volume":"13","author":"K Nabrdalik","year":"2022","unstructured":"Nabrdalik K, Skonieczna-\u017bydecka K, Irlik K, Hendel M, Kwiendacz H, \u0141oniewski I, Lip GY (2022) Gastrointestinal adverse events of Metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of randomized controlled trials. Front Endocrinol 13:975912","journal-title":"Front Endocrinol"},{"issue":"3","key":"2525_CR35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14656566.2021.1999413","volume":"23","author":"B Tomlinson","year":"2022","unstructured":"Tomlinson B, Patil NG, Fok M, Chan P, Lam CWK (2022) The role of sulfonylureas in the treatment of type 2 diabetes. Expert Opin Pharmacother 23(3):387\u2013403","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"2525_CR36","first-page":"P25","volume":"13","author":"PL Madhuri","year":"2023","unstructured":"Madhuri PL, Rajitha G (2023) The intriguing Thiazolidinediones as PPAR \u03b3 agonists: A Review.(2023). Int J Life Sci Pharma Res 13(5):P25\u2013P50","journal-title":"Int J Life Sci Pharma Res"},{"issue":"15","key":"2525_CR37","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3390\/ijerph16152720","volume":"16","author":"K Makrilakis","year":"2019","unstructured":"Makrilakis K (2019) The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect. Int J Environ Res Public Health 16(15):2720","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"2525_CR38","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1365-2265.2008.03235.x","volume":"69","author":"A Vella","year":"2008","unstructured":"Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan M, Camilleri LM (2008) The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol 69(5):737\u2013744","journal-title":"Clin Endocrinol"},{"key":"2525_CR39","doi-asserted-by":"crossref","unstructured":"Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, Pang MG (2021) Role of insulin in health and disease: an update. Int J Mol Sci 22(12):6403","DOI":"10.3390\/ijms22126403"},{"key":"2525_CR40","unstructured":"Drugs.com (2022) Insulin side effects. https:\/\/www.drugs.com\/sfx\/insulin-side-effects.html#refs"},{"key":"2525_CR41","doi-asserted-by":"crossref","unstructured":"Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE,Bennett DL, Viswanathan V (2019) Diabetic neuropathy. Nat Rev Dis Primers 5(1):1\u201318","DOI":"10.1038\/s41572-019-0092-1"},{"key":"2525_CR42","doi-asserted-by":"publisher","first-page":"102718","DOI":"10.1016\/j.autneu.2020.102718","volume":"229","author":"CS Marathe","year":"2020","unstructured":"Marathe CS, Jones KL, Wu T, Rayner CK, Horowitz M (2020) Gastrointestinal autonomic neuropathy in diabetes. Auton Neurosci 229:102718","journal-title":"Auton Neurosci"},{"issue":"2","key":"2525_CR43","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1172\/JCI27758","volume":"116","author":"CK Rayner","year":"2006","unstructured":"Rayner CK, Horowitz M (2006) Gastrointestinal motility and glycemic control in diabetes: the chicken and the egg revisited? J Clin Investig 116(2):299\u2013302","journal-title":"J Clin Investig"},{"key":"2525_CR44","unstructured":"Schroeder EB (2022) Management of type 2 diabetes: selecting amongst available Pharmacological agents. Endotext [Internet]"},{"issue":"18","key":"2525_CR45","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M (2023) Risk of Gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330(18):1795\u20131797","journal-title":"JAMA"},{"key":"2525_CR46","doi-asserted-by":"crossref","unstructured":"Hurtado I, Robles C, Peir\u00f3 S, Garc\u00eda-Sempere A, Sanf\u00e9lix-Gimeno G (2024) Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study. Diabetologia 1\u201310","DOI":"10.1007\/s00125-024-06243-z"},{"issue":"6","key":"2525_CR47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","volume":"19","author":"MA Hern\u00e1n","year":"2008","unstructured":"Hern\u00e1n MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, Robins JM (2008) Observational studies analyzed like randomized experiments:an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 19(6):766\u2013779","journal-title":"Epidemiology"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02525-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:16:34Z","timestamp":1764180994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02525-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":47,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["2525"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02525-z","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}